| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the last three months, 6 analysts have published ratings on BeiGene (NASDAQ:BGNE), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 2 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $212.88, along with a high estimate of $345.00 and a low estimate of $161.00. A decline of 6.98% from the prior average price target is evident in the current average.
The perception of BeiGene by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yaron Werber | TD Cowen | Raises | Buy | $236.00 | $235.00 |
| David Li | B of A Securities | Lowers | Neutral | $164.30 | $179.30 |
| Rebecca Liang | Bernstein | Lowers | Market Perform | $161.00 | $196.00 |
| Jessica Fye | JP Morgan | Raises | Overweight | $186.00 | $184.00 |
| Michael Schmidt | Guggenheim | Lowers | Buy | $345.00 | $350.00 |
| Jessica Fye | JP Morgan | Announces | Overweight | $185.00 | - |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of BeiGene's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on BeiGene analyst ratings.
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: BeiGene's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 66.91%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: BeiGene's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -57.94%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): BeiGene's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -10.07%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): BeiGene's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.49%, the company may face hurdles in achieving optimal financial performance.
Debt Management: BeiGene's debt-to-equity ratio is below the industry average at 0.26, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BGNE
